Abbott Laboratories vs Johnson & Johnson (ABT vs JNJ)
Side by side from their SEC filings: revenue, margins, growth, returns and valuation, plus short interest, insider activity and institutional ownership.
Johnson & Johnson is the larger company by revenue ($94.2B vs $44.3B) and market value ($653.5B vs $188.5B). Johnson & Johnson has grown revenue faster over the last 4 fiscal years (+19.6% cumulative vs +2.9%). Johnson & Johnson trades at the lower trailing P/E (30.9x vs 35.3x).
About Abbott Laboratories
Abbott Laboratories develops, manufactures, and sells a wide range of healthcare products globally. Its main business segments include established pharmaceutical products sold primarily outside the U.S., diagnostic systems and tests used in various healthcare settings, nutritional products for infants and adults, and medical devices for cardiovascular, diabetes care, and neuromodulation treatments. The company serves customers such as healthcare providers, government agencies, consumers, and distributors worldwide.
About Johnson & Johnson
Johnson & Johnson is a global healthcare company that operates through two main segments: Innovative Medicine and MedTech. The Innovative Medicine segment develops and sells prescription medicines for various therapeutic areas including oncology, immunology, neuroscience, infectious diseases, and cardiovascular conditions. The MedTech segment designs and manufactures medical devices and products used in cardiovascular care, orthopaedics, surgery, and vision, serving healthcare professionals, hospitals, and eye care providers worldwide.
Head to head (ABT FY2025 vs JNJ FY2025)
| Metric | ABTFY2025 | JNJFY2025 |
|---|---|---|
| Revenue | $44.33B | $94.19B |
| Revenue growth (YoY) | 5.7% | 6.0% |
| Gross margin | 56.4% | 67.9% |
| Operating margin | 18.2% | — |
| Net margin | 14.7% | 28.5% |
| Net income | $6.52B | $26.80B |
| Diluted EPS | $3.72 | $11.03 |
| FCF margin | 16.7% | 20.9% |
| ROE | 12.4% | 32.9% |
| Long-term debt / equity | 0.19× | 0.48× |
| Market cap | $188.49B | $653.54B |
| P/E | 35.3× | 30.9× |
Fundamentals are from each company’s SEC filings (ABT FY2025, JNJ FY2025). ROE is net income over fiscal-year-end equity; long-term debt / equity counts non-current term debt only. P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.
Five-year trend (as reported)
| Revenue | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| ABT | $43.08B | $43.65B | $40.11B | $41.95B | $44.33B |
| JNJ | $78.74B | $79.99B | $85.16B | $88.82B | $94.19B |
Peer standing
Where each company ranks among the 198 pharmaceutical companies, on the same scale. Each figure is ranked only against peers that report it. Percentiles describe position in the distribution, not a rating.
| Metric | ABT | JNJ |
|---|---|---|
| Gross margin | 56.4%40th percentile of 69 | 67.9%51st percentile of 69 |
| Net margin | 14.7%77th percentile of 122 | 28.5%83rd percentile of 122 |
| FCF margin | 16.7%70th percentile of 110 | 20.9%80th percentile of 110 |
| Revenue growth (YoY) | +5.7%41st percentile of 187 | +6.0%43rd percentile of 187 |
| ROE | 12.4%78th percentile of 167 | 32.9%90th percentile of 167 |
| P/E | 35.3×73rd percentile of 60 | 30.9×68th percentile of 60 |
| Long-term debt / equity | 0.19×32nd percentile of 64 | 0.48×48th percentile of 64 |
| Short interest (days to cover) | 2.86d24th percentile of 197 | 3.33d28th percentile of 197 |
Short interest
| FINRA settlement data | ABT | JNJ |
|---|---|---|
| Shares sold short | 20.4M | 21.6M |
| Change vs prior settlement | -9.9% | -15.0% |
| Days to cover | 2.86 | 3.33 |
| As of settlement | 2026-08-14 | 2026-08-14 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data; republishing or redistributing it is not permitted. Not presented as a percentage of float. No FINRA endorsement of this product is implied.
Insider activity (last 90 days)
| Form 4 activity (codes P/S) | ABT | JNJ |
|---|---|---|
| Buys | 0 | 0 |
| Sells | 3 ($46.8M) | 9 ($61.0M) |
Non-derivative purchases (code P) and sales (code S) reported on SEC Form 4, which may be open-market or private (grants, exercises and tax withholding excluded). For context, about 15% of covered companies saw any reported insider purchase (code P) in a 90-day window.
Held by the same investors
9 tracked 13F managers hold both Abbott Laboratories and Johnson & Johnson as of their latest quarterly filings: AQR Capital Management, Bridgewater Associates, Citadel Advisors, D. E. Shaw, Dodge & Cox, Gotham Asset Management, Millennium Management, Soros Fund Management, Two Sigma Investments. See which superinvestors hold your own portfolio with the smart money checker.
Go deeper
ABBV vs ABTABT vs BMYABT vs LLYABT vs MRKABT vs PFEABT vs VRTXAll pharmaceutical stocks →All comparisons →
Track ABT and JNJ
Get an alert when either company files something material, see which superinvestors own them, and ask their filings a question with cited answers.
Start monitoring freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filings before relying on them. Comparisons are descriptive (higher or lower on a reported figure), not a rating or a recommendation. Informational only. Not investment advice.